Erratum to: The Multi Centre Canadian Acellular Dermal Matrix Trial (MCCAT): study protocol for a randomized controlled trial in implant-based breast reconstruction.

Toni Zhong,John Semple,Nancy Baxter,Stefan O P Hofer,Claire Temple-Oberle,Colleen Mccarthy,Brett Beber,Mitchell Brown,Sheina Macadam,Peter Lennox,Tony Panzarella

doi:10.1186/s13063-016-1179-6

Abstract

The two-stage tissue expander/implant (TE/I) reconstruction is currently the gold standard method of implant-based immediate breast reconstruction in North America. Recently, however, there have been numerous case series describing the use of one-stage direct to implant reconstruction with the aid of acellular dermal matrix (ADM). In order to rigorously investigate the novel application of ADM in one-stage implant reconstruction, we are currently conducting a multicentre randomized controlled trial (RCT) designed to evaluate the impact on patient satisfaction and quality of life (QOL) compared to the two-stage TE/I technique. The MCCAT study is a multicenter Canadian ADM trial designed as a two-arm parallel superiority trial that will compare ADM-facilitated one-stage implant reconstruction compared to two-stage TE/I reconstruction following skin-sparing mastectomy (SSM) or nipple-sparing mastectomy (NSM) at 2 weeks, 6 months, and 12 months. The source population will be members of the mastectomy cohort with stage T0 to TII disease, proficient in English, over the age of 18 years, and planning to undergo SSM or NSM with immediate implant breast reconstruction. Stratified randomization will maintain a balanced distribution of important prognostic factors (study site and unilateral versus bilateral procedures). The primary outcome is patient satisfaction and QOL as measured by the validated and procedure-specific BREAST-Q. Secondary outcomes include short- and long-term complications, long-term aesthetic outcomes using five standardized photographs graded by three independent blinded observers, and a cost effectiveness analysis. There is tremendous interest in using ADM in implant breast reconstruction, particularly in the setting of one-stage direct to implant reconstruction where it was previously not possible without the intermediary use of a temporary tissue expander (TE). This unique advantage has led many patients and surgeons alike to believe that one-stage ADM-assisted implant reconstruction should be the procedure of choice and should be offered to patients as the first-line treatment. We argue that it is crucial that this technique be scientifically evaluated in terms of patient selection, surgical technique, complications, aesthetic outcomes, cost-effectiveness, and most importantly patient-reported outcomes before it is promoted as the new gold standard in implant-based breast reconstruction. ClinicalTrials.gov: NCT00956384

Highlights

Erratum After publication of this work [1], we noted that we failed to include the middle initials of the author, Stefan O.P
* Correspondence: toni.zhong@uhn.ca 1Division of Plastic and Reconstructive Surgery, University Health Network, Toronto, ON, Canada Full list of author information is available at the end of the article
Submit your manuscript to BioMed Central and we will help you at every step:

Summary

Introduction

Erratum After publication of this work [1], we noted that we failed to include the middle initials of the author, Stefan O.P. Erratum to: The Multi Centre Canadian Acellular Dermal Matrix Trial (MCCAT): study protocol for a randomized controlled trial in implant-based breast reconstruction P. Hofer1, Brett Beber1, John Semple1, Mitchell Brown1, Sheina Macadam3, Peter Lennox3, Tony Panzarella4, Colleen McCarthy5, Nancy Baxter6 and For the MCCAT Study Group

Results

Conclusion